SKB BIO-B (06990.HK) +6.600 (+1.989%) Short selling $126.69M; Ratio 31.932% announced on June 5 that it had entered into a placing agreement to issue 5.918 million new H shares of the company, representing approximately 2.54% of the company's enlarged issued share capital, at a price of HKD331.8 per share, which was about a 7.58% discount to the previous closing price of HKD359 per share.The net proceeds from the placing were expected to reach approximately HKD1.943 billion. The Company intended to use the estimated net proceeds of the placing for the research and development, clinical trials, registration filings, manufacturing and commercialization of its products; to enhance its internal research and development technology capabilities, strengthen external collaboration, and expand its product pipeline portfolio; and to replenish working capital and for general corporate purposes.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-06 16:25.)Related NewsCCBI Lists Low-valued, High Div. 'Defensive' Picks Among HK Stocks (Table)